keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28320215/correction-to-psoriasis-patients-with-psoriasis-area-and-severity-index-pasi-90-response-achieve-greater-health-related-quality-of-life-improvements-than-those-with-pasi-75-89-response-results-from-two-phase-3-studies-of-secukinumab
#1
https://www.readbyqxmd.com/read/28301043/a-topical-treatment-optimisation-programme-ttop-improves-clinical-outcome-to-calcipotriol-betamethasone-gel-in-psoriasis-results-of-the-64-week-multinational-randomized-phase-iv-study-in-1790-patients-pso-top
#2
K Reich, I Zschocke, H Bachelez, E M G J de Jong, P Gisondi, L Puig, R B Warren, C Ortland, U Mrowietz
BACKGROUND: Around two-thirds of psoriasis patients do not adhere to topical treatment. The 'Topical Treatment Optimisation Programme' (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/email helpdesks and treatment reminders. It has been developed by patients and dermatologists to help increase adherence in psoriasis. OBJECTIVE: To compare TTOP with standard of care ('non-TTOP') within a large European investigator-initiated study, PSO-TOP (Clinicaltrials...
March 16, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28300857/evaluation-of-the-physician-global-assessment-and-body-surface-area-composite-tool-for-assessing-psoriasis-response-to-apremilast-therapy-results-from-esteem-1-and-esteem-2
#3
Kristina C Duffin, Kim A Papp, Jerry Bagel, Eugenia Levi, Rongdean Chen, Alice B Gottlieb
BACKGROUND: The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity. OBJECTIVE: To evaluate the product of PGAxBSA as a sensitive alternative to the Psoriasis Area and Severity Index (PASI) for assessing disease severity and therapeutic response with data collected from the phase 3 ESTEEM 1 and 2 trials. METHODS: This post hoc analysis included 836 patients randomized to apremilast 30 mg BID at baseline (ESTEEM 1, n=562; ESTEEM 2, n=274)...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28300302/quality-of-life-instruments-in-psoriasis-clinical-trials
#4
D Kivelevitch, P Michel, A Menter
No abstract text is available yet for this article.
March 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28294430/rapid-improvements-in-health-related-quality-of-life-and-itch-with-ixekizumab-treatment-in-randomized-phase-3-trials-results-from-uncover-2-and-uncover-3
#5
C L Leonardi, A Blauvelt, H L Sofen, M Gooderham, M Augustin, R Burge, B Zhu, K Reich
BACKGROUND: Patients with moderate-to-severe psoriasis report impaired health-related quality of life (HRQoL). OBJECTIVE: To assess speed of onset of ixekizumab-induced clinically relevant improvement in HRQoL. METHODS: This post-hoc analysis used pooled data from patients randomized in UNCOVER-2 and UNCOVER-3, and treated with 80 mg ixekizumab every 2 weeks (IXEQ2W), 80 mg ixekizumab every 4 weeks (IXEQ4W), 50 mg etanercept (ETN) twice weekly, or placebo (PBO) for 12 weeks...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28291975/quality-of-life-of-persons-suffering-from-schizophrenia-psoriasis-and-physical-disabilities
#6
Tija Žarković Palijan, Dražen Kovačević, Mirela Vlastelica, Elizabeta Dadić-Hero, Marijana Sarilar
BACKGROUND: Studies have addressed the impact of chronic diseases and their treatment on quality of life (Qol), but the relative impact of different chronic conditions on patients' level of subjective functioning is mostly unknown. Stigma is associated with poor Qol in various chronic diseases. The aim of this study was to compare the quality of life of people suffering from schizophrenia with the quality of life of patients with psoriasis and physical disabilities. SUBJECTS AND METHODS: Study was conducted on a sample of 88 persons suffering from schizophrenia, 60 persons with physical disabilities and 57 persons with psoriasis...
March 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28290219/2-crisaborole-topical-ointment-for-the-treatment-of-mild-to-moderate-atopic-dermatitis
#7
Alice C Cheape, Dedee F Murrell
Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle...
March 14, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28281329/addiction-an-underestimated-problem-in-psoriasis-healthcare
#8
A Zink, M Herrmann, T Fischer, F Lauffer, N Garzorz-Stark, A Böhner, C D Spinner, T Biedermann, K Eyerich
BACKGROUND: Psoriasis is a disease of enormous socio-economic impact. Despite approval of numerous highly efficient and costly therapies, a minor proportion of severely affected patients actually receives sufficient treatment. OBJECTIVE: To investigate whether addictions are associated with psoriasis and to develop evidence-based recommendations for dermatologists in their daily clinical practice in order to improve medical assessment of psoriasis and patients' quality of life...
March 9, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28273375/characteristics-of-patient-receiving-ustekinumab-compared-with-secukinumab-for-treatment-of-moderate-to-severe-plaque-psoriasis-nationwide-results-from-the-dermbio-registry
#9
A Egeberg, L Iversen, R Gniadecki, L Hvid, T N Dam, L E Bryld, L Skov
BACKGROUND: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking. OBJECTIVE: We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab. METHODS: All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28271561/a-european-subset-analysis-from-the-population-based-multinational-assessment-of-psoriasis-and-psoriatic-arthritis-mapp-shows-country-specific-features-results-from-psoriasis-patients-in-spain
#10
L Puig, P C M van de Kerkhof, K Reich, H Bachelez, J Barker, G Girolomoni, C F Paul
BACKGROUND: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). OBJECTIVE: Utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). METHODS: MAPP was conducted between June and August 2012. This analysis included 1700 patients with self-reported psoriasis (without psoriatic arthritis) from France (n=349), Germany (n=311), Italy (n=359), Spain (n=354) and the United Kingdom (n=327)...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28266782/systemic-immune-mechanisms-in-atopic-dermatitis-and-psoriasis-with-implications-for-treatment
#11
REVIEW
Emma Guttman-Yassky, James G Krueger, Mark G Lebwohl
Atopic dermatitis (AD) and psoriasis are inflammatory skin diseases that negatively affect patients' quality of life. Although distinctions exist between these diseases, both are characterised by erythematous, thickened epidermal lesions that vary in intensity and affected body surface area. Early models of etiology attributed symptoms of both diseases to cutaneous inflammation at lesion sites, but recent studies have established that activated immune mediators in the circulation drive disease severity. Activation of T helper 2 (Th2) and Th22 cells in the circulation appears to be the principal initiator of acute AD pathology, with the emergence of Th1 and Th17/interleukin (IL)-23 pathway activation marking the transition to a chronic state...
March 7, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28266243/psoriasis-patients-with-psoriasis-area-and-severity-index-pasi-90-response-achieve-greater-health-related-quality-of-life-improvements-than-those-with-pasi-75-89-response-results-from-two-phase-3-studies-of-secukinumab
#12
Boni E Elewski, Lluís Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis, Bruce E Strober
BACKGROUND: The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL). OBJECTIVE: To evaluate the association of greater response in skin clearance with improvements in skin-related QOL up to 52 weeks. METHODS: Subjects achieving various levels of skin clearance (PASI 90-100 or PASI 75-89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data...
March 7, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28262172/alexithymia-in-different-dermatologic-patients
#13
Fahimeh Dehghani, Farideh Dehghani, Parichehr Kafaie, Mohammad Reza Taghizadeh
Alexithymia is a personality trait characterized by difficulties in differentiating and describing feelings. Research indicates that alexithymia can be considered as a possible risk factor for a variety of medical conditions. The purpose of our study was to compare and assess the prevalence of alexithymia in patients with psoriasis, alopecia areata, vitiligo and acne vulgaris. 120 consecutive subjects referred to dermatologic clinic with psoriasis, alopecia areata, vitiligo and acne vulgaris and 30 subjects selected from hospital staff and relatives of patients were enrolled in patient and control groups of our study respectively...
February 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28240341/factors-influencing-cardiometabolic-risk-profile-in-patients-with-psoriasis
#14
Neus Curcó, Nuria Barriendos, Maria José Barahona, Carmen Arteaga, Mercedes García, Stanislav Yordanov, Olimpia De La Barrera, Carolina Prat, Pere Vives, Nuria Giménez
BACKGROUND: Psoriasis has been associated with metabolic syndrome and with an increased cardiovascular risk especially in patients with severe disease. The goal of this study was to estimate the prevalence of metabolic syndrome and other cardiovascular risk factors and its association with the psoriasis severity, sex and age. METHODS: Consecutive patients with psoriasis were enrolled in a prospective study over a 1-year period. Blood samples were collected. Psoriasis area and severity index (PASI) and body surface area scores and two dermatology quality of life (DQOL) questionnaires were used to evaluate psoriasis severity and the impact of the disease...
February 27, 2017: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/28236223/calcipotriol-plus-betamethasone-dipropionate-aerosol-foam-in-patients-with-moderate-to-severe-psoriasis-sub-group-analysis-of-the-pso-able-study
#15
Carle Paul, Craig Leonardi, Alan Menter, Kristian Reich, Linda Stein Gold, Richard B Warren, Anders Møller, Mark Lebwohl
BACKGROUND: Fixed-combination calcipotriol 50 μg/g plus betamethasone 0.5 mg/g (Cal/BD) aerosol foam is a new topical treatment for psoriasis. Although moderate-to-severe psoriasis is typically treated with systemic/biologic therapies, a topical treatment that is efficacious in these patients may be a significant cost-saving alternative to systemic therapy. OBJECTIVE: The objective of this study was to assess the response to Cal/BD foam and gel in patients with moderate-to-severe psoriasis enrolled in the phase III, 12-week PSO-ABLE study...
February 24, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28213862/apremilast-a-review-in-psoriasis-and-psoriatic-arthritis
#16
Gillian M Keating
Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast...
March 2017: Drugs
https://www.readbyqxmd.com/read/28196270/open-label-study-of-etanercept-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-who-lost-a-satisfactory-response-to-adalimumab
#17
J Bagel, S Tyring, K C Rice, D H Collier, G Kricorian, J Chung, J Iles, B S Stolshek, A Kaliyaperumal, K A Papp
BACKGROUND: Some plaque psoriasis patients experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety, and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. METHODS: This phase 4, open-label, single-arm, estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static physician global assessment (sPGA) score 0/1 (clear/almost clear)...
February 14, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28192600/systematic-reviews-and-meta-analyses-on-psoriasis-role-of-funding-sources-conflict-of-interest-and-bibliometric-indices-as-predictors-of-methodological-quality
#18
F Gómez-García, J Ruano, M Aguilar-Luque, J Gay-Mimbrera, B Maestre-Lopez, J L Sanz-Cabanillas, P J Carmona-Fernández, M González-Padilla, A Vélez García-Nieto, B Isla-Tejera
BACKGROUND: The quality of systematic reviews (SRs) and meta-analyses about psoriasis, a chronic inflammatory skin disease that severely impairs quality of life and is associated with high costs, remains unknown. OBJECTIVES: To assess the methodological quality of SRs published on psoriasis. METHODS: After a comprehensive search in MEDLINE, EMBASE, and the Cochrane Database (PROSPERO:CDR4201604161), the quality was assessed by two raters using Assessment of Multiple Systematic Reviews (AMSTAR) tool...
February 13, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28182255/fatigue-in-psoriasis-a-controlled-study
#19
I M Skoie, I Dalen, T Ternowitz, G Jonsson, I Kvivik, K Norheim, R Omdal
BACKGROUND: Fatigue is associated with various chronic inflammatory diseases, but few studies have focused on its occurrence in psoriasis. OBJECTIVES: To describe fatigue prevalence and degree among patients with chronic plaque psoriasis compared with age- and gender-matched healthy subjects, and to examine how fatigue is influenced by essential clinical and demographic factors. METHODS: In 84 patients and 84 healthy subjects, fatigue severity was assessed using three different generic fatigue instruments: the fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) vitality scale...
February 9, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28181669/characteristics-and-risk-profile-of-psoriasis-patients-included-in-the-czech-national-registry-biorep-and-a-comparison-with-other-registries
#20
Martina Kojanova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Jitka Jircikova, Tomas Dolezal, Petr Arenberger
BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST...
February 9, 2017: International Journal of Dermatology
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"